Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update
Anavex Life Sciences Corp. (AVXL)
NASDAQ:AMEX Investor Relations:
anavex.com/share-data
Company Research
Source: GlobeNewswire
Company to host a webcast today at 8:30 am Eastern Time NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today reported financial results for its first quarter of fiscal 2026. “As we have entered 2026, we continue to progress our innovative clinical pipeline with particular focus on our lead candidate, oral blarcamesine in early Alzheimer's disease. Based on our commitment to improving the lives of patients with neurological disorders, we remain excited about the therapeutic potential of oral blarcamesine. We look forward to working with the regulatory agencies in Europe and the U.S. to advance oral blarcamesine as a potential new treatment
Show less
Read more
Impact Snapshot
Event Time:
AVXL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVXL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVXL alerts
High impacting Anavex Life Sciences Corp. news events
Weekly update
A roundup of the hottest topics
AVXL
News
- Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
- Anavex: Negative EU Opinion Leaves Blarcamesine In Regulatory Purgatory [Seeking Alpha]Seeking Alpha
- Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $24.00 price target on the stock.MarketBeat
- Anavex Life Sciences Q1 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Anavex Life Sciences: Fiscal Q1 Earnings Snapshot [Yahoo! Finance]Yahoo! Finance
AVXL
Earnings
- 2/9/26 - Beat
AVXL
Sec Filings
- 2/9/26 - Form 10-Q
- 2/9/26 - Form 8-K
- 1/9/26 - Form 4
- AVXL's page on the SEC website